Blood test could spot cartilage cancer early, without radiation
NCT ID NCT07492823
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a blood test (liquid biopsy) can help diagnose and monitor cartilage tumors called chondrosarcomas. Researchers will collect blood samples from 60 patients before and after surgery, and during follow-up for two years. They will look for specific genetic changes in the blood to see if the test can tell tumor types apart and detect if the cancer comes back.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHONDROSARCOMA OF THE BONE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Orthopaedics and Trauma
Graz, Styria, 8036, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill stall advanced sarcomas?
- Experimental drug tested for rare cancer, trial stopped early
- New hope for rare bone cancer? drug shows promise in early trial
- Scientists hunt for better ways to diagnose and treat rare bone tumors
- Could your own tumor cells fight cancer? new trial tests immune cell therapy
- Could a common bone drug help fight a rare cancer?